JF
ADMA icon

Jump Financial’s ADMA Biologics ADMA Stock Holding History

Jump Financial’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.51M Sell
180,000
-265,077
-60% -$2.42M 0.01% 1009
2026
Q1 		$4.01M Buy
445,077
+278,886
+168% +$4.4M 0.05% 420
2025
Q4 		$3.03M Sell
166,191
-193,634
-54% -$3.26M 0.04% 526
2025
Q3 		$5.28M Buy
+359,825
New +$6.17M 0.06% 388
2025
Q2 		– Sell
-357,256
Closed -$7.09M – 1766
2025
Q1 		$7.09M Buy
357,256
+333,752
+1,420% +$5.77M 0.09% 263
2024
Q4 		$403K Buy
+23,504
New +$442K 0.01% 1179
2024
Q3 		– Sell
-77,105
Closed -$862K – 1597
2024
Q2 		$862K Sell
77,105
-259,767
-77% -$2.18M 0.02% 887
2024
Q1 		$2.22M Buy
336,872
+83,160
+33% +$455K 0.06% 396
2023
Q4 		$1.15M Sell
253,712
-6,713
-3% -$24.8K 0.04% 647
2023
Q3 		$932K Buy
260,425
+58,718
+29% +$226K 0.03% 701
2023
Q2 		$744K Buy
201,707
+170,697
+550% +$633K 0.03% 833
2023
Q1 		$103K Sell
31,010
-82,614
-73% -$286K ﹤0.01% 1435
2022
Q4 		$441K Buy
+113,624
New +$350K 0.02% 838
2022
Q2 		– Sell
-34,900
Closed -$64K – 1565
2022
Q1 		$64K Buy
+34,900
New +$54.4K ﹤0.01% 1451

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Jump Financial's ADMA Position: Q2 2026 in Review

Jump Financial reduced its ADMA Biologics (ADMA) stake by 60% in Q2 2026, selling an estimated $2.42M and leaving 180,000 shares worth $1.51M. The position accounts for 0.01% of the portfolio, ranked #1009.

Jump Financial first reported a position in ADMA in Q1 2022 and has held it in 14 quarters since. The position peaked at $7.09M in Q1 2025. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Jump Financial held 180,000 shares of ADMA Biologics worth $1.51M as of Q2 2026.
  • Jump Financial sold 265,077 ADMA Biologics shares in Q2 2026, an estimated $2.42M.
  • ADMA Biologics made up 0.01% of Jump Financial's portfolio in Q2 2026, its #1009 holding.
  • Jump Financial first reported a position in ADMA Biologics in Q1 2022 and has held it in 14 quarters since.
  • Jump Financial's ADMA Biologics position peaked at $7.09M in Q1 2025.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Jump Financial's 13F filing for Q2 2026, filed 13 Aug 2026.